

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY DOCKET NO. TSRI 481.2	SERIAL NO. 09/194,552
	APPLICANT Brooks, et al.	
	FILING DATE March 23, 1999	GROUP 1642

U.S. PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
anh	95/14714	6/1/95	PCT	—	—	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

anh	10	Hammes, et al., Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization, 1996, <i>Nature Med.</i> , 2(5):529-533.
anh	11	Brooks, et al., Integrin $\alpha v \beta 3$ antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels, 1994, <i>Cell</i> , 79:1157-1164.
anh	12	Clark, et al, Transient functional expression of $\alpha v \beta 3$ on vascular cells during wound repair, 1996, <i>Am. J Pathol.</i> , 148:1407-1421.
anh	13	Bauer, et al., In vitro model of angiogenesis using a human endothelium-derived permanent cell line: contributions of induced gene expression, G-proteins and integrins, 1992, <i>J. Cell. Physiol.</i> , 153:437-449.
anh	14	Ingber, Extracellular matrix as a solid state regulator of angiogenesis: identification of new targets for anti-cancer therapy, 1992, <i>Seminars in Cancer Biology</i> , 3:57-63.
anh	15	Hardan, et al., Inhibition of metastatic cell colonization in murine lungs and tumor-induced morbidity by non-peptidic Arg-Gly-Asp mimetics, 1993, <i>Intl. J. Cancer</i> , 55:1023-1028.
anh	16	Hynes, Integrins: versatility, modulation, and signaling in cell adhesion, 1992, <i>Cell</i> , 69:11-25.
anh	17	Lehmann, et al., A monoclonal antibody inhibits adhesion to fibronectin and vitronectin of a colon carcinoma cell line and recognizes the integrins $\alpha v \beta 3$, $\alpha v \beta 5$ and $\alpha v \beta 6$, 1994, <i>Cancer Res.</i> , 54:2102-2107.
EXAMINER: <i>amotassi</i>		DATE CONSIDERED: <i>October 9, 2001</i>

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY DOCKET NO. TSRI 481.2	SERIAL NO. 09/194,552
	APPLICANT Brooks, et al.	
	FILING DATE March 23, 1999	GROUP 1642

U.S. PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

amb	18	Pierschbacher, et al., Influence of stereochemistry of the sequence Arg-Gly-Asp-Xaa on binding specificity in cell adhesion, 1987, <i>J. Biol. Chem.</i> , 262:17294-17296.
amb	19	Folkman, et al., Angiogenesis, 1992, <i>J. Biol. Chem.</i> , 267:10931-10934.
amb	20	Teicher, et al., Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents, 1994, <i>Intl. J. Cancer</i> , 57:920-925.
amb	21	Drake, et al., A antagonist of integrin $\alpha\beta 3$ prevent maturation of blood vessels during embryonic neovascularization, 1995, <i>J. Cell Sci.</i> , 108:2655-2661.
amb	22	Folkman, et al., Inhibition of angiogenesis, 1992, <i>Cancer Bio.</i> , 3:89-96.
amb	23	Aumailley, et al., Arg-Gly-Asp constrained within cyclic pentapeptides: strong and selective inhibitors of cell adhesion to vitronectin and laminin-fragment P1, 1991, <i>FEBS</i> , 291(1):50-54.
amb	24	Choi, et al., Inhibition of neointimal hyperplasia by blocking $\alpha\beta 3$ integrin with a small peptide antagonist GpenGRGDSPCA, 1994, <i>J. Vasc. Surg.</i> , 19:125-134.
	25	
	26	
EXAMINER <i>amb</i>		DATE CONSIDERED <i>October 3, 2001</i>

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<div style="display: flex; justify-content: space-between;"> <div> <p>FORM PTO-1449</p> <p>U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> </div> <div style="text-align: center;"> <p>U.S. PATENT AND TRADEMARK OFFICE</p> <p>JUN 11 2001</p> </div> </div>					ATTY DOCKET NO. TSR 481.0		SERIAL NO. 08/514,799	
					APPLICANT Brooks, et al.			
					FILING DATE 8/14/95		GROUP Unknown 1692	

U.S. PATENT DOCUMENTS							
EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
<i>amh</i>		4,517,686	5/21/85	Ruoslahti			
		4,578,079	3/25/86	Ruoslahti			
		4,589,881	5/20/86	Pierschbacher			
		4,614,517	9/30/86	Ruoslahti			
		4,661,111	4/28/87	Ruoslahti			
		4,683,291	7/28/87	Zimmerman			

FOREIGN PATENT DOCUMENTS							
EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	FILING DATE

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)		
<i>amh</i>	1	Brooks, et al., "Subtractive Immunization Yields Monoclonal Antibodies that Specifically Inhibit Metastasis", J. Cell Biology, 122: 1351-1359 (1993)
	2	Brooks, et al., Requirement of Vascular Integrin Alpha v Beta 3 for Angiogenesis" Science, 264: 569-571 (1994)
	3	Brown, et al., "Expression of Vascular Permeability Factor (Vascular Endothelial Growth Factor) and its Receptors in Breast Cancer", Human Path., 26:86 (1995)
	4	Cheng, et al., "Human Microvascular Endothelial Cells Express Integrin-Related Complexes that Mediate Adhesion to the Extracellular Matrix", J. Cell Physiol., 139: 275-286 (1989)
<i>V</i>	5	Cheresh, David A., "Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and

EXAMINER <i>amh</i>	DATE CONSIDERED <i>October 3, 2001</i>
------------------------	---

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE JUN 11 2001 INFORMATION DISCLOSURE STATEMENT BY APPLICANT				ATTY DOCKET NO. TSR 481.0		SERIAL NO. 08/514,799	
				APPLICANT Brooks, et al.			
				FILING DATE 8/14/95		GROUP unknown 1642	

U.S. PATENT DOCUMENTS							
EXAM. INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE	
amh	4,792,525	12/20/88	Ruoslahti				
	4,879,237	11/7/89	Ruoslahti				
	4,988,621	1/29/91	Ruoslahti				
	5,041,380	8/20/91	Ruoslahti				
	5,061,693	10/29/91	Nutt				

FOREIGN PATENT DOCUMENTS							
EXAM. INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	FILING DATE	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)		
amh		von Willebrand factor", Proc. Natl. Acad. Sci., USA, 84: 6471-6475 (1987)
5	6	Davis, et al., "Identification of a Role of the Vitronectin Receptor and Protein Kinase C in the Induction of Endothelial Cell Vascular Formation", J. Cellular Biochemistry, 51: 206-218 (1993)
	7	Horton, Michael, "Current Status Review Vitronectin receptor: tissue specific expression or adaptation to culture?", Int. J. Exp. Path., 71: 741-759 (1990)
	8	Janat, et al., "Regulation of Vascular Smooth Muscle Cell Integrin Expression by Transforming Growth Factor beta 1 by Platelet-Derived Growth Factor-BB", J. Cellular Physiol., 151: 588-595 (1992)
	9	Nicosia, et al., "Rapid Communication: Inhibition of Angiogenesis in vitro by Arg-Gly-Asp-Containing Synthetic Peptide", Am. J. Path., 138: 829-833 (1991)

EXAMINER amh	DATE CONSIDERED October 9, 2001
-----------------	------------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY DOCKET NO.
TSR 481.0SERIAL NO.
08/514,799APPLICANT
Brooks, et al.INFORMATION DISCLOSURE
STATEMENT BY APPLICANTFILING DATE
8/14/95GROUP
~~unknown~~ 1642

U.S. PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	FILING DATE

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

amh	10	Pasqualini, et al., "A study of the structure, function and distribution of beta 5 integrins using novel anti-beta 5 monoclonal antibodies", J. Cell Science, 105: 101-111 (1993)
	11	Pfaff, et al., "Selective Recognition of Cyclic RGD Peptides of NMR Defined Conformation by α IIbB3, α VB3, and α 5B1 Integrins", J. Biol. Chem., 269: 20233-20238 (1994)
	12	Wayner, et al., "Integrins α vB3 and α vB5 Contribute to Cell Attachment to Vitronectin but Differentially Distribute on the Cell Surface", Journ. of Cell Biol., 113: 919-929 (1991)

EXAMINER

amharris

DATE CONSIDERED

October 3, 2001

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY DOCKET NO. TSRI 481.2	SERIAL NO. 09/194,552
	APPLICANT Brooks, et al.	
	FILING DATE March 23, 1999	GROUP 1642

U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
amh	AA	5,575,815	11/19/96	Slepian, et al.	—	—	
↓	AB	5,849,692	12/15/98	Jonczyk, et al.	—	—	
amh	AC	5,968,902	10/19/99	Scarborough, et al.	—	—	
amh	AD	5,981,478	11/9/99	Ruoslahti, et al.	—	—	
amh	AE	5,866,540	2/2/99	Jonczyk, et al.	—	—	
amh	AF	5,135,919	8/4/92	Folkman, et al.	—	—	

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO
amh	AG	95/28426	10/26/95	PCT	—	—	
↓	AH	97/14716	4/24/97	PCT	—	—	
amh	AI	0 770 622 A	5/2/97	EPO	—	—	entire document in German
amh	AJ	89/06536	7/27/89	PCT	—	—	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

amh	1	Matsuno, et al., Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation, 1994, <i>Circulation</i> , 90(5):2203-2205.
↓	2	Timar, et al., The antimetabolite tiazofurin (TR) inhibits glycoconjugate biosynthesis and invasiveness of tumour cells, 1996, <i>Eur. J. Cancer</i> , 32A(1):152-159.
amh	3	Aimes, et al., Cloning of a 72 kDa matrix metalloproteinase (gelatinase) from chicken embryo fibroblasts using gene family PCR: expression of the gelatinase increases upon malignant transformation, 1994, <i>Biochem J.</i> , 300:729-736.
↓	4	Friedlander, et al., Definition of two angiogenic pathways by distinct α v integrins, 1995, <i>Science</i> , 270:1500-1502.
amh	5	Pfaff, et al., Comparison of disintegrins with limited variation in the RGD loop in their binding to purified integrins α IIb β 3, α v β 3 and α 5 β 1 and in cell adhesion inhibition, 1994, <i>Cell Adhes. Commun.</i> , 2(6):491-501.
↓	6	Smith, et al., Interaction of integrins α v β 3 and glycoprotein IIb-IIIa with fibrinogen, 1990, <i>J. Biol. Chem.</i> , 265:12267-12271.
amh	7	Mueller, et al., Pre-clinical therapy of human melanoma with morpholino-doxorubicin conjugated to a monoclonal antibody directed against an integrin on melanoma cells, <i>Antibody, Immunoconjugates, and Radiopharmaceuticals</i> , 1991, 4(2):99-106.
↓	8	Ossowski, et al., Experimental model for quantitative study of metastasis, 1980, <i>Cancer Res.</i> , 40:2300-2309.
↓	9	Klein, et al., Basic fibroblast growth factor modulates integrin expression in microvascular endothelial cells, 1993, <i>Mol. Biol. Cell</i> , 4:973-982.
EXAMINER		DATE CONSIDERED
amh		October 9, 2001

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.